BioNTech reported a Q1 2026 net loss of $622.3 million as revenue declined to $138.0 million and R&D spending rose to $651.6 million. The company expanded its oncology pipeline with five new pivotal trials for pumitamig and announced manufacturing site exits to save $584.9 million annually by 2029.
Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05919264 |
FOG-001 in Locally Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT04895709 |
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT03104439 |
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
